Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13427504 | 0.94 | LPL (0.32) | LPLLIPGKDM4EMEN1ALDH1A1 | |
| SCHEMBL13427603 | 0.93 | AKT1 (0.38) | LPLLIPGPTGER3KDM4EMEN1 | |
| SCHEMBL13427435 | 0.93 | LPL (0.36) | LPLLIPGPTGER3KDM4EMEN1 | |
| SCHEMBL13427280 | 0.92 | LPL (0.32) | LPLLIPG | |
| SCHEMBL13008711 | 0.92 | LPL (0.36) | LPLLIPGPTGER3KDM4EMEN1 | |
| SCHEMBL13428162 | 0.91 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13009317 | 0.91 | MET (0.31) | — | |
| SCHEMBL13009384 | 0.91 | BCHE (0.31) | — | |
| SCHEMBL13427510 | 0.91 | PDK2 (0.32) | — | |
| SCHEMBL13008853 | 0.91 | ALDH1A1 (0.32) | PTGER3KDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256176-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | RPL36, RPL39, RPL36A | LPL 4521/4885LIPG 4672/4885PTGER3 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.